August 30, 2023

High drug price associated with decreased treatment retention for patients with chronic liver disease

Researchers from the University of Minnesota Medical School and College of Pharmacy have found that high costs for hepatic encephalopathy treatment in patients with end-stage liver disease were associated with decreased treatment retention for patients. The study results were recently published in Hepatology Communications. Hepatic encephalopathy is the loss of brain function that occurs in people with severe liver disease. The […]

admin Health 0 1 min read
August 6, 2023

Livmarli receives Health Canada authorization for Alagille syndrome – Mirum Pharmaceuticals

Health Canada has authorized the use of maralixibat oral solution (Livmarli) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), as recently announced by Mirum Pharmaceuticals. Health Canada’s authorization is based on data from the pivotal ICONIC study, which includes 6 years of data from the maralixibat clinical program. The study has provided robust evidence demonstrating statistically […]

admin Health 0 21 sec read
July 18, 2023

Mulpleta approved in China to treatthrombocytopenia in adult patients with chronic liver disease – Eddingpharm

Shionogi announced that its Chinese license partner Eddingpharm has won regulatory approval for its thrombopoietin receptor agonist Mulpleta (lusutrombopag) in China. The drug was approved for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an elective invasive procedure. Originated by Shionogi, Mulpleta is a small molecule agonist of the human thrombopoietin […]

admin Health 0 38 sec read
June 24, 2023

FDA approves Bylvay for patients living with cholestatic pruritus due to Alagille syndrome – Ipsen

Ipsen announced that the FDA has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS). Bylvay is a once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) that acts locally in the small intestine and has minimal systemic exposure. Bylvay was approved as the first drug treatment option for patients […]

admin Health 0 2 min read
May 21, 2023

New analysis of trial of semaglutide in adolescents shows it can reduce liver enzymes indicative of liver damage

A new substudy of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) shows that adolescents using semaglutide experienced significant reductions in levels of liver enzymes that are an indicator of liver damage. The study is by Dr Daniel Weghuber, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria, and Dr Rasmus Sørrig, […]

admin Health 0 2 min read
April 25, 2023

For NASH, bariatric surgery is more effective than drug treatment or lifestyle intervention

Bariatric surgery treats advanced non-alcoholic fatty liver disease (NASH) significantly more effectively than drug or lifestyle intervention, researchers reported on April 20, 2023 in The Lancet. Professor Francesco Rubino, MD, a senior co-investigator and Chair of Bariatric and Metabolic Surgery at King’s College in London said, “The presence of NASH predicts a significant risk of complications and mortality in people […]

admin Health 0 1 min read
April 24, 2023

Surgery most effective treatment of metabolic liver disease

Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease. A new paper, published today in The Lancet by King’s College London and the Catholic University of Rome, is the first to compare three active treatments of non-alcoholic Steatohepatitis (NASH) and to specifically investigate the effectiveness of metabolic surgery (weight […]

admin Health 0 2 min read
November 24, 2022

Bariatric surgery lowers risk of cardiovascular disease

New research involving adults diagnosed with nonalcoholic fatty liver disease (NAFLD) and morbid obesity (body mass index > 40) indicates that subjects who had bariatric surgery achieved a significantly reduced risk of developing subsequent cardiovascular disease (CVD). The findings appeared on Oct. 5, 2022 in JAMA Network Open. “The findings provide evidence in support of bariatric surgery as an effective […]

admin Health 0 1 min read
November 22, 2022

Novel AI blood test detects liver cancer

A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now detected more than 80% of liver cancers in a new study of 724 people. The blood test, called DELFI (DNA evaluation of fragments for early interception) detects fragmentation changes among DNA from […]

admin Health 0 5 min read
September 25, 2022

Cold method for clearer fatty liver observation found

Obesity can give rise to a variety of health concerns. Nonalcoholic steatohepatitis (NASH)—a type of fatty liver disease that might progress to cancer—is particularly prevalent among obese people. Treatment for NASH patients has yet to be found, due partly to the absence of suitable and efficient methods to isolate and analyze characteristics of hepatic stellate cells (HSCs), which are proven […]

admin Health 0 1 min read

Recent Posts

Meta

Categories

Archives

Recent Comments